Which hedge funds own VIR? VIR BIOTECHNOLOGY INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
7 of the hedge funds tracked by WhaleCreep disclosed a position in VIR (VIR BIOTECHNOLOGY INC) in their Q2 2026 13F filings, worth $88.5m in total. The largest holder by portfolio weight is Avidity Partners at 0.8% of its book. 1 manager opened a new position this quarter: Brevan Howard Capital Management. 2 exited: Farallon Capital Management, Tudor Investment.
7tracked managers holding
1opened this quarter
2exited this quarter
Which hedge funds hold VIR? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Avidity Partners | Q2 2026 | 0.8% | $5.3m | 519,300 | -45% | reduced |
| Point72 Asset Management LP | Q2 2026 | 0.1% | $57.7m | 5,666,821 | 190% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $10.4m | 1,016,864 | 34% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $10.1m | 991,337 | -53% | reduced |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $220.1k | 21,598 | – | new |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $4.2m | 416,403 | -49% | reduced |
| Millennium Management | Q2 2026 | 0.0% | $489.0k | 47,993 | -90% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Farallon Capital Management | 0.0% | $197.1k |
| Tudor Investment | 0.0% | $658.6k |
Held in a manager's last filing on record
These managers have not filed for the latest quarter; their last disclosure is dated.
| Manager | Last filing | Weight |
|---|---|---|
| Caxton Associates | Q4 2024 | 0.0% |
How has hedge fund ownership of VIR changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 7 | $88.5m |
| Q1 2026 | 8 | $64.2m |
| Q4 2025 | 3 | $5.3m |
| Q3 2025 | 1 | $6.7m |
| Q2 2025 | 1 | $5.4m |
| Q1 2025 | 3 | $10.7m |
| Q4 2024 | 4 | $16.8m |
| Q3 2024 | 5 | $45.5m |
| Q2 2024 | 5 | $13.8m |
| Q1 2024 | 5 | $15.5m |
| Q4 2023 | 3 | $14.0m |
| Q3 2023 | 4 | $14.4m |
| Q2 2023 | 5 | $81.2m |
| Q1 2023 | 4 | $110.7m |
| Q4 2022 | 3 | $55.2m |
| Q3 2022 | 3 | $32.6m |
Counts every tracked manager that disclosed VIR in that quarter's filing, including managers that have since stopped filing.